Press Releases

• Jul 25, 2017 AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
• Jul 17, 2017 AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
• Jun 5, 2017 AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
• May 1, 2017 AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
• Mar 22, 2017 AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
• Dec 15, 2016 AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
• Sep 22, 2016 AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
• Jun 29, 2016 AntriaBio Announces $12 Million Private Placement
• Jun 22, 2016 AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
• Jan 6, 2016 AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations